News Headlines Article

An Increase in Scrutiny for Generics
The New York Times

The Food and Drug Administration said it was looking more closely at the way generic companies made extended-release drugs after it found one such medicine failed to work as well as its brand-name counterpart. The finding is a rare departure for the agency, which for years has insisted that generic drugs are just as effective as their brand-name versions.

The drug, a 300-milligram dose of bupropion, was manufactured by Impax Laboratories and was intended to mimic the popular antidepressant, Wellbutrin XL. But soon after it was introduced in 2006, patients who switched to it from Wellbutrin began complaining that their depression had returned.